 Otonomy, Inc. OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the status and timeline to results for the companys three ongoing clinical trials including the Phase 3 trial of OTIVIDEX in Ménières disease at 4:30 p.m. EDT 1:30 p.m. PDT on June 15, 2020. This call is consistent with Otonomys previously announced plan to provide an update on the timing guidance, which had been pulled in April as a result of the COVID-19 pandemic. The live call may be accessed by dialing 877 305-6769 for domestic callers and 678 562-4239 for international callers with conference ID code number: 3655435. 